Actively Recruiting
The Effect of Hyperbaric Oxygen Therapy on Circulating Hematopoietic Stem Cell Population
Led by Assaf-Harofeh Medical Center · Updated on 2026-04-21
60
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hematopoietic stem cells (HSCs), which govern the production of all blood lineages, transition through a series of functional states characterized by expansion during fetal development, functional quiescence in adulthood, and decline upon aging. Although research on aging has for a long time been relatively descriptive, much progress has been made in the past decade to uncover the molecular drivers of biological aging. One such drivers relates to stem cell exhaustion. The amount and the function of HSCs decline in humans along aging. This decline is characterized by different changes such as signaling, epigenetic, cell surface markers etc. Various studies have been conducted to identify HSCs surface markers using flow cytometry. Exposure to Hyperbaric Oxygen Therapy (HBOT) induce stem cells proliferation mobilization of stem progenitor cells (SPCs) in both animal and humans studies, and the number of SPCs remain elevated in blood over the course of 20 HBOT . Additionally, Heyboer et al have found dose response curve between the HBOT protocol and circulating CD34+ and CD45-dim (stem cells potential markers): increasing the treatment pressure from 2.0 ATA to 2.5 ATA increased the concentration of circulating stem cells. The aim of the current study is to evaluate the effect of HBOT on circulating hematopoietic stem cells, in the peripheral blood of patients who are candidate for HBOT.
CONDITIONS
Official Title
The Effect of Hyperbaric Oxygen Therapy on Circulating Hematopoietic Stem Cell Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 20 to 80 years
- Patients planning to start Hyperbaric Oxygen Therapy for another medical reason
- Willingness to provide blood samples for stem cell measurements
You will not qualify if you...
- Active or recent infection within the last month
- Active malignancy
- History of hematopoietic disease
- Low vitamin B12 or iron levels
- Inability to sign the informed consent form
- White blood cell count less than 4,000 or greater than 10,000
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)
Zrifin, Israel, 70300
Actively Recruiting
Research Team
S
Shai Efrati, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here